Biomark Diagnostics Stock Annual Yield
| BMKDF Stock | USD 0.15 0.01 6.25% |
BioMark Diagnostics fundamentals help investors to digest information that contributes to BioMark Diagnostics' financial success or failures. It also enables traders to predict the movement of BioMark Pink Sheet. The fundamental analysis module provides a way to measure BioMark Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioMark Diagnostics pink sheet.
BioMark |
BioMark Diagnostics Company Annual Yield Analysis
BioMark Diagnostics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, BioMark Diagnostics has an Annual Yield of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Diagnostics & Research (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
BioMark Fundamentals
| Return On Asset | -1.45 | |||
| Operating Margin | (15.72) % | |||
| Current Valuation | 12.8 M | |||
| Shares Outstanding | 83.29 M | |||
| Shares Owned By Insiders | 54.77 % | |||
| Price To Earning | (8.80) X | |||
| Price To Sales | 105.81 X | |||
| Revenue | 43.93 K | |||
| Gross Profit | 43.93 K | |||
| EBITDA | (1.22 M) | |||
| Net Income | (1.45 M) | |||
| Cash And Equivalents | 364.96 K | |||
| Total Debt | 96.3 K | |||
| Current Ratio | 0.35 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (1.2 M) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 0.66 | |||
| Market Capitalization | 11.74 M | |||
| Total Asset | 1.47 M | |||
| Retained Earnings | (3.47 M) | |||
| Working Capital | (461 K) | |||
| Current Asset | 19 K | |||
| Current Liabilities | 480 K | |||
| Z Score | 69.8 | |||
| Net Asset | 1.47 M |
About BioMark Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioMark Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioMark Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioMark Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in BioMark Pink Sheet
BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.